Life Science Funding Weakness Hit Azenta’s (AZTA) Outlook

Life Science Funding Weakness Hit Azenta’s (AZTA) Outlook

Thu, August 6, 2026 at 4:30 PM GMT+3 3 min read

• ^RUT -0.59%
• AZTA +5.61%

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm and semiconductor stocks. However, market leadership was uneven, mirroring the Tech Bubble, with high-beta stocks outperforming while high-quality companies lagged, which impacted Conestoga's quality-focused strategies. Management expressed confidence in long-term outcomes, noting that speculative leadership won't last as monetary policy tightens and market breadth improves. The firm remains committed to high-quality growth businesses, expecting these to regain favor as leadership broadens. The Conestoga Small Cap Composite returned 14.32% net-of-fees in the second quarter, with 25.71% for the Russell 2000 Growth Index. Narrow Index leadership hurt the relative results, but it also hid Composite improvements. In addition, please check the Strategy's top five holdings to know its best picks in 2026.

In its Q2 2026 investor letter, Conestoga Capital Advisors highlighted Azenta, Inc. (NASDAQ:AZTA). The firm sold its position in Azenta, Inc. (NASDAQ:AZTA), a US-based life science company that focuses on biological and chemical compound sample exploration and management solutions, this quarter. On August 5, 2026, Azenta, Inc. (NASDAQ:AZTA) closed at $31.82 per share, reflecting a market capitalization of $1.47 billion. Azenta, Inc. (NASDAQ:AZTA) posted a one-month return of 25.18%, while its shares gained 9.23% over the past 52 weeks.

Conestoga Capital Advisors stated the following regarding Azenta, Inc. (NASDAQ:AZTA) in its Q2 2026 investor letter:

"Azenta, Inc. (NASDAQ:AZTA) provides sample management, cold-chain, and multiomics solutions for the life sciences industry. We sold the position after execution challenges, weaker life sciences funding, and continued softness in capital equipment demand led management to lower its full year outlook. Although the company is implementing operational improvements, we believed the recovery would likely take longer than originally anticipated."

Azenta, Inc. (NASDAQ:AZTA) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 26 hedge fund portfolios held Azenta, Inc. (NASDAQ:AZTA) at the end of the first quarter, compared to 32 in the previous quarter. While we acknowledge the potential of Azenta, Inc. (NASDAQ:AZTA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

In another article, we covered Azenta, Inc. (NASDAQ:AZTA) and shared a list of best medical stocks to buy under $30. The Azenta, Inc. (NASDAQ:AZTA) detracted from Conestoga Capital Advisors' performance in the previous quarter as operational challenges and uneven execution pressured profitability. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. This article is originally published at Insider Monkey.